Unknown

Dataset Information

Endpoints for randomized controlled clinical trials for COVID-19 treatments.


ABSTRACT:

Background

Endpoint choice for randomized controlled trials of treatments for novel coronavirus-induced disease (COVID-19) is complex. Trials must start rapidly to identify treatments that can be used as part of the outbreak response, in the midst of considerable uncertainty and limited information. COVID-19 presentation is heterogeneous, ranging from mild disease that improves within days to critical disease that can last weeks to over a month and can end in death. While improvement in mortality would provide unquestionable evidence about the clinical significance of a treatment, sample sizes for a study evaluating mortality are large and may be impractical, particularly given a multitude of putative therapies to evaluate. Furthermore, patient states in between "cure" and "death"

SUBMITTER: Dodd LE 

PROVIDER: S-EPMC7611901 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature